Charles River Laboratories International, Inc.
- Last sale
- Nov 9, 2026 · +4.76%
- Market cap
- $16.94B
- 47.92M shares
- Filings
- 1,067
Q3 2026−0.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−88.9% FY25 yoy
Q3 2026derived+3.4% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+9.8% FY25 yoy
- $16.94B
- 421.4×
- 4.3×
- 5.2×
- 2.36%
- —
Twelve months to Sep 26, 2026 · derived
Price
Nov 9, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-27 | $4,015,382,000 | reported | |
| FY 2024 | 2024-12-28 | $4,049,989,000 | reported | |
| FY 2023 | 2023-12-30 | $4,129,409,000 | reported | |
| FY 2022 | 2022-12-31 | $3,976,060,000 | reported | |
| FY 2021 | 2021-12-25 | $3,540,160,000 | reported | |
| FY 2020 | 2020-12-26 | $2,923,933,000 | reported | |
| FY 2019 | 2019-12-28 | $2,621,226,000 | reported | |
| FY 2018 | 2018-12-29 | $2,266,096,000 | reported | |
| FY 2017 | 2017-12-30 | $1,857,601,000 | reported | |
| FY 2016 | 2016-12-31 | $1,681,432,000 | reported | |
| FY 2015 | 2015-12-26 | $1,363,302,000 | reported | |
| FY 2014 | 2014-12-27 | $1,297,662,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $360.67M | $360.67M | — | 49.23M sh | −3.7% | 69.6% |
| FY2024 | — | $119.18M | $119.18M | — | 51.14M sh | −0.4% | 23.8% |
| FY2023 | — | $24.16M | $24.16M | — | 51.35M sh | +0.7% | 6.6% |
| FY2022 | — | $38.65M | $38.65M | — | 50.99M sh | +1.0% | 13.1% |
| FY2021 | — | $40.71M | $40.71M | — | 50.49M sh | +1.4% | 7.7% |
Segments
LineFY2025ShareChange
DSA$2.40B60%−2.0%
RMS$846.08M21%+2.0%
Manufacturing$766.41M19%−0.4%
DSA———
Manufacturing———
RMS———
Total$4.02B
Commercial physical & biological research
Charles River Laboratories International, Inc. is the 4th largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731
CompanyRevenueGrowthNet marginMarket cap
IQVIQVIA Holdings Inc.$16.3B5.9%8.3%$44.7BICLRIcon PLC$8.3B0.8%2.8%—INCYIncyte Corp$5.1B21.2%25.0%$24.8B
CRLCharles River Laboratories International, Inc. (this company)$4.0B0.9%3.6%$16.9B
MEDPMedpace Holdings, Inc.$2.5B20.0%17.8%$18.4BNRCNRC Health$137.4M4.0%8.4%$566.4MMXCTMaxcyte, Inc.$33.0M14.5%135.1%$121.8MOABIOmniAb, Inc.$18.7M29.3%347.0%$721.3MFOXOFoxo Technologies Inc.$16.4M304.0%75.9%—Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Charles River Laboratories International, Inc. · CIK 1100682 · Engraved from SEC EDGAR